197 related articles for article (PubMed ID: 38191799)
21. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
22. Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2.
Liu H; Yang PS; Zhu T; Manuel J; Zhang J; He W; Shalev I; Zhang L; Cybulsky MI; Grant DR; Phillips MJ; Levy GA
Int J Biochem Cell Biol; 2013 Feb; 45(2):408-18. PubMed ID: 23127799
[TBL] [Abstract][Full Text] [Related]
23. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
[TBL] [Abstract][Full Text] [Related]
24. Clara Cell 10 kDa Protein Alleviates Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis by Inhibiting Fibrinogen-Like Protein 2 Expression.
Yu H; Liu Y; Wang H; Wan X; Huang J; Yan W; Xi D; Luo X; Shen G; Ning Q
Front Immunol; 2018; 9():2935. PubMed ID: 30619295
[No Abstract] [Full Text] [Related]
25. Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis.
Liu Y; Xu L; Zeng Q; Wang J; Wang M; Xi D; Wang X; Yang D; Luo X; Ning Q
Liver Int; 2012 Nov; 32(10):1585-95. PubMed ID: 22925132
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of fibrinogen-like protein 2 alleviates acute rejection in rat models of liver transplantation.
Zhang X; Ma J; Li H; Zhou L; Liu Z; Lyu S; He Q; Li X
Ann Transl Med; 2021 Mar; 9(5):408. PubMed ID: 33842629
[TBL] [Abstract][Full Text] [Related]
27. Fibrinogen-like protein 2 deficiency inhibits virus-induced fulminant hepatitis through abrogating inflammatory macrophage activation.
Xiao F; Wang HW; Hu JJ; Tao R; Weng XX; Wang P; Wu D; Wang XJ; Yan WM; Xi D; Luo XP; Wan XY; Ning Q
World J Gastroenterol; 2022 Jan; 28(4):479-496. PubMed ID: 35125831
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
30. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
31. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells.
Chan CW; Kay LS; Khadaroo RG; Chan MW; Lakatoo S; Young KJ; Zhang L; Gorczynski RM; Cattral M; Rotstein O; Levy GA
J Immunol; 2003 Apr; 170(8):4036-44. PubMed ID: 12682232
[TBL] [Abstract][Full Text] [Related]
32. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
Wenthe J; Eriksson E; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Loskog A
J Transl Med; 2023 Jul; 21(1):506. PubMed ID: 37501121
[TBL] [Abstract][Full Text] [Related]
33. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
34. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer.
Gao Y; Shi H; Zhao H; Yao M; He Y; Jiang M; Li J; Li Z; Su S; Liu T; Yin C; Liao X; Yue W
Clin Transl Med; 2023 Sep; 13(9):e1416. PubMed ID: 37712139
[TBL] [Abstract][Full Text] [Related]
35. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory function of Tregs via soluble FGL2 in chronic hepatitis B.
Xu L; Yang D; Liu Y; Wu D; Wang X; Ning Q
J Huazhong Univ Sci Technolog Med Sci; 2012 Aug; 32(4):540-545. PubMed ID: 22886967
[TBL] [Abstract][Full Text] [Related]
37. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
38. FGL2 regulates IKK/NF-κB signaling in intestinal epithelial cells and lamina propria dendritic cells to attenuate dextran sulfate sodium-induced colitis.
Li T; Chen RR; Gong HP; Wang BF; Wu XX; Chen YQ; Huang ZM
Mol Immunol; 2020 Jan; 117():84-93. PubMed ID: 31743856
[TBL] [Abstract][Full Text] [Related]
39. sFgl2 gene-modified MSCs regulate the differentiation of CD4
Ji W; Wang W; Li P; Liu Y; Zhang B; Qi F
Stem Cell Res Ther; 2023 Nov; 14(1):316. PubMed ID: 37924141
[TBL] [Abstract][Full Text] [Related]
40. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
